News & Media

Follow our news


News

2024-06-25

PolTREG will get access to new groups of type-1 diabetes patients with its Treg cellulartherapies after signing a cooperation deal with the University Clinical Center in Gdansk

See

2024-06-24

Positive results of a long-term safety and efficacy study of PTG-007 in early-onset type-1 diabetes

See

2024-06-13

PolTREG received approval to operate a genetic engineering facility from Poland’s ministry of Climate and Environment

See

2024-05-14

PolTREG received a patent in the US protecting the manufacturing of T-regulatory cells to treat Type-1 Diabetes, and ways the therapy is administered

See

2024-04-05

PolTREG identifies promising efficacy biomarker for Type-1 diabetes in patients treatedwith its Treg therapy in combination with rituximab

See

2024-03-11

PolTREG’s state-of-the-art manufacturing facility has received approval to produce cellulartherapies from the Chief Pharmaceutical Inspectorate in Poland.

See

2024-02-21

PolTREG appoints Dan Shelly, PhD, MBA as Chief Business Development Officer to help it build partnerships across industry and deliver milestones

See

2024-02-07

Global institutional investors and investment funds hold over 25% of PolTREG’s shares.

See

2024-01-30

Prof. Piotr Trzonkowski co-authors peer-reviewed article showing scientific progress in T-regautoimmune therapy

See

2024-01-16

PolTREG receives US Patent Office Notice of Allowance for Treg cell therapy to treat Type-1 Diabetes

See

2024-01-15

The J.P. Morgan Healthcare Conference 2024 is already behind us!

See

2024-01-02

PolTREG at J.P. Morgan Healthcare Conference

See

Materials
for Media

PolTREG logo

Download

PolTREG Leadership team

Download

Contact for Media

ir@poltreg.com